| Abstract [eng] |
Introduction. Glioblastoma is the most aggressive primary malignant brain tumour, characterized by rapid progression and poor survival outcomes. Patients experience profound physical, cognitive, and emotional changes that significantly impact their quality of life. In recent years, quality of life assessment has become essential in medical research and clinical practice, providing insights into the disease’s impact and improving symptom management. Clinical case presentation. This case report describes a 77-year-old patient diagnosed with grade IV glioblastoma. The patient presented with progressive neurological symptoms, including headaches, cognitive decline, and motor dysfunction. Clinical and radiological examinations confirmed a brain tumour. Histopathological analysis following surgical resection identified grade IV glioblastoma with a TERT promoter mutation and an IDH wild-type phenotype. After temozolomide monotherapy, follow-up MRI confirmed tumour progression. Given the patient’s clinical status and treatment options, palliative chemotherapy with lomustine was initiated. The patient’s quality of life was assessed using the EORTC QLQ-C30 and QLQ-BN20 questionnaires to monitor subjective well-being. Conclusion. Glioblastoma profoundly affects patients’ quality of life due to progressive physical, cognitive, and emotional deterioration. The impact of treatment is dynamic—while postoperative decline is common, certain phases may allow for temporary stabilization or improvement. Key factors contributing to reduced quality of life include fatigue, communication difficulties, motor impairment, and uncertainty about the future. As the disease progresses, quality of life worsens, with the most significant decline observed after tumour recurrence. |
